Immunological aspects of cancer chemotherapy

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

A cytokine-mediated link between innate immunity, inflammation, and cancer

Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625

Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis

Yu, X., Zhang, Z., Wang, Z., Wu, P., Qiu, F., & Huang, J. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1391-y · Cited by 137

Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients

Piersma, S. J. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0066-7 · Cited by 140

Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment

Cui, Y. R., & Guo, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111942 · Cited by 137

Role of Fcγ receptors in HER2-targeted breast cancer therapy

Musolino, A., Gradishar, W. J., Rugo, H. S., Nordstrom, J. L., Rock, E. P., Arnaldez, F. I., & Pegram, M. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003171 · Cited by 142

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons

Funt, S. A., & Rosenberg, J. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.188 · Cited by 134

A Biomimetic Polymer Magnetic Nanocarrier Polarizing Tumor‐Associated Macrophages for Potentiating Immunotherapy

Liu, L., Wang, Y., Guo, X., Zhao, J., & Zhou, S. (2020) · Small · doi:10.1002/smll.202003543 · Cited by 133

Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies

Gebremeskel, S., & Johnston, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6113 · Cited by 139

Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation

Tanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1106 · Cited by 134

Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Lee, H. J., Seo, J. Y., Ahn, J., Ahn, S. H., & Gong, G. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.1.32 · Cited by 132

The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy

Hu, L., Cao, Z., Ma, L., Liu, Z., Liao, G., Wang, J., Shen, S., Li, D., & Yang, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119469 · Cited by 132

Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1–PD-L1 Axis

Ding, Z., Lu, X., Yu, M., Lemos, H. D. P., Huang, L., Chandler, P., Liu, K., Walters, M. J., Krasinski, A., Mack, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3596 · Cited by 135

Multidrug Resistance in Cancer

Baguley, B. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_1 · Cited by 131

Chemotherapy remains an essential element of personalized care for persons with lung cancers

Hellmann, M. D., Li, B., Chaft, J. E., & Kris, M. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw271 · Cited by 136

Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine

Chen, H., Wang, P.-H., Chen, S.-S., Wen, C.-C., Chen, Y., Yang, W., & Yang, N. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1258-9 · Cited by 138

Synergistic Induction of Adaptive Antitumor Immunity by Codelivery of Antigen with α-Galactosylceramide on Exosomes

Gehrmann, U., Hiltbrunner, S., Georgoudaki, A., Karlsson, M. C. I., Näslund, T. I., & Gabrielsson, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3918 · Cited by 130

Biopolymers based aerogels: A review on revolutionary solutions for smart therapeutics delivery

Khalil, H. P. S. A., Yahya, E. B., Jummaat, F. B., Adnan, A. S., Olaiya, N. G., Rizal, S., Abdullah, A. A., Pasquini, D., & Thomas, S. (2022) · Progress in Materials Science · doi:10.1016/j.pmatsci.2022.101014 · Cited by 137

Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms

Fridlender, Z. G., Sun, J., Singhal, S. K., Kapoor, V., Cheng, G., Suzuki, E., & Albelda, S. Μ. (2010) · Molecular Therapy · doi:10.1038/mt.2010.159 · Cited by 129

Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer

Cappello, P., Rolla, S., Chiarle, R., Principe, M., Cavallo, F., Perconti, G., Feo, S., Giovarelli, M., & Novelli, F. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.020 · Cited by 110

Harnessing the exosome-induced immune response for cancer immunotherapy

Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.003 · Cited by 111

The Predictive Value of Pre-treatment Inflammatory Markers in Advanced Non-small-Cell Lung Cancer

Kasymjanova, G., Macdonald, N., Agulnik, J. S., Cohen, V., Pepe, C., Kreisman, H., Sharma, R., & Small, D. (2010) · Current Oncology · doi:10.3747/co.v17i4.567 · Cited by 127

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

Ascierto, P. A., Simeone, E., Giannarelli, D., Grimaldi, A. M., Romano, A., & Mozzillo, N. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-107 · Cited by 131

The Tumor-Immune Microenvironment and Response to Radiation Therapy

Shiao, S. L., & Coussens, L. M. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9194-9 · Cited by 127

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance

Zingoni, A., Fionda, C., Borrelli, C., Cippitelli, M., Santoni, A., & Soriani, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01194 · Cited by 126

Muc1 Immunotherapy

Beatson, R., Taylor‐Papadimitriou, J., & Burchell, J. (2010) · Immunotherapy · doi:10.2217/imt.10.17 · Cited by 125

Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis

Yu, Y., Cheng, Q., Ji, X., Chen, H., Zeng, W., Zeng, X., Zhao, Y., & Mei, L. (2022) · Science Advances · doi:10.1126/sciadv.add3599 · Cited by 126

Why Target Immune Cells for Plasma Treatment of Cancer

Miller, V., Lin, A. G., & Fridman, A. (2015) · Plasma Chemistry and Plasma Processing · doi:10.1007/s11090-015-9676-z · Cited by 120

Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape

Olaussen, K. A., & Postel-Vinay, S. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw321 · Cited by 124

Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death

Tu, K., Deng, H., Kong, L., Wang, Y., Yang, T., Hu, Q., Hu, M. Y., Yang, C., & Zhang, Z. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b23084 · Cited by 122

From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment

Fabian, K. P., Wolfson, B., & Hodge, J. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.728018 · Cited by 131

Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects

Kujawski, M., Zhang, C., Herrmann, A., Reckamp, K. L., Scuto, A., Jensen, M. C., Deng, J., Forman, S. J., Figlin, R. A., & Yu, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1293 · Cited by 123

Immuno‐Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents

Wong, D. Y. Q., Yeo, C. H. F., & Ang, W. H. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402879 · Cited by 120

A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia

Shah, N. J., Najibi, A. J., Shih, T., Mao, A. S., Sharda, A., Scadden, D. T., & Mooney, D. J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0503-3 · Cited by 123

Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions

Poleszczuk, J., Luddy, K. A., Prokopiou, S., Robertson‐Tessi, M., Moros, E. G., Fishman, M., Djeu, J. Y., Finkelstein, S. E., & Enderling, H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1423 · Cited by 119

Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers

Abdo, J., Cornell, D. L., Mittal, S. K., & Agrawal, D. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00085 · Cited by 122

Immunogenicity of anthracyclines: moving towards more personalized medicine

Apétoh, L., Mignot, G., Panaretakis, T., Kroemer, G., & Zitvogel, L. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.002 · Cited by 130

Uniform Nanosecond Pulsed Dielectric Barrier Discharge Plasma Enhances Anti‐Tumor Effects by Induction of Immunogenic Cell Death in Tumors and Stimulation of Macrophages

Lin, A. G., Truong, B., Pappas, A., Kirifides, L., Oubarri, A., Chen, S., Lin, S., Dobrynin, D., Fridman, G., Fridman, A., et al. (2015) · Plasma Processes and Polymers · doi:10.1002/ppap.201500139 · Cited by 120

The immunogenicity of tumor cell death

Kepp, O., Tesnière, A., Zitvogel, L., & Kroemer, G. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32831bc375 · Cited by 124

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study

Nicola, M. D., Zappasodi, R., Carlo‐Stella, C., Mortarini, R., Pupa, S. M., Magni, M., Devizzi, L. F., Matteucci, P., Baldassari, P., Ravagnani, F., et al. (2008) · Blood · doi:10.1182/blood-2008-06-165654 · Cited by 116

Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies

Pascolo, S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.12.017 · Cited by 116

Immunogenic Cell Death: Can It Be Exploited in PhotoDynamic Therapy for Cancer?

Panzarini, E., Inguscio, V., & Dini, L. (2012) · BioMed Research International · doi:10.1155/2013/482160 · Cited by 120

The CD4-like molecule LAG-3, biology and therapeutic applications

Sierro, S. R., Romero, P. J., & Speiser, D. E. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712598.2011.540563 · Cited by 115

Engineering Prodrug Nanomedicine for Cancer Immunotherapy

Yang, B., Gao, J., Pei, Q., Xu, H., & Yu, H. (2020) · Advanced Science · doi:10.1002/advs.202002365 · Cited by 116

Functional precision oncology using patient-derived assays: bridging genotype and phenotype

van Renterghem, A. W. J., van de Haar, J., & Voest, E. E. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00745-2 · Cited by 121

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

Christiansen, A. J., West, A. C., Banks, K.-M., Haynes, N. M., Teng, M. W. L., Smyth, M. J., & Johnstone, R. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011037108 · Cited by 114

An integrated humoral and cellular response is elicited in pancreatic cancer by α‐enolase, a novel pancreatic ductal adenocarcinoma‐associated antigen

Cappello, P., Tomaino, B., Chiarle, R., Ceruti, P., Novarino, A., Castagnoli, C., Migliorini, P., Perconti, G., Giallongo, A., Milella, M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24355 · Cited by 114

Vincristine-induced peripheral neuropathy: A mini-review

Li, G.-Z., Hu, Y., Li, D.-Y., Zhang, Y., Guo, H., Li, Y., Chen, F., & Xu, J. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.10.004 · Cited by 114

Lapatinib and doxorubicin enhance the S tat1‐dependent antitumor immune response

Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M.-H., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242505 · Cited by 113

Tumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy

Escors, D. (2014) · New Journal of Science · doi:10.1155/2014/734515 · Cited by 119

Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape

Ghiringhelli, F., Bruchard, M., Chalmin, F., & Rébé, C. (2012) · BioMed Research International · doi:10.1155/2012/473712 · Cited by 120

Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients

Kyte, J. A., Gaudernack, G., Dueland, S., Trachsel, S., Julsrud, L., & Aamdal, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0184 · Cited by 111

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes

Galsky, M. D., Wang, H., Hahn, N. M., Twardowski, P. W., Pal, S. K., Albany, C., Fleming, M. T., Starodub, A., Hauke, R. J., Yu, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.12.001 · Cited by 113

Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy

Vincent, M. P., Navidzadeh, J. O., Bobbala, S. K. R., & Scott, E. A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.006 · Cited by 117

Harnessing γδ T cells in anticancer immunotherapy

Hannani, D., Ma, Y., Yamazaki, T., Déchanet‐Merville, J., Kroemer, G., & Zitvogel, L. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.006 · Cited by 117

Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells

Chu, J., He, S., Deng, Y., Zhang, J., Peng, Y., Hughes, T. L., Yi, L., Kwon, C.-H., Wang, Q.-E., Devine, S. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2510 · Cited by 111

Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies

Jang, B., Kwon, H., Katila, P., Lee, S. J., & Lee, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.023 · Cited by 111

Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response

Godet, Y., Fabre, E., Dosset, M., Lamuraglia, M., Levionnois, É., Ravel, P., Benhamouda, N., Cazes, A., Pimpec‐Barthes, F. L., Gaugler, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3185 · Cited by 131

The emerging role of immune checkpoint inhibition in malignant lymphoma

Hude, I., Sasse, S., Engert, A., & Bröckelmann, P. J. (2016) · Haematologica · doi:10.3324/haematol.2016.150656 · Cited by 109

An in situ hydrogel-mediated chemo-immunometabolic cancer therapy

Wang, B., Chen, J., Caserto, J. S., Wang, X., & Ma, M. (2022) · Nature Communications · doi:10.1038/s41467-022-31579-8 · Cited by 111

Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer

Leon-Ferre, R. A., Polley, M. C., Liu, H., Gilbert, J. A., Cafourek, V., Hillman, D. W., Elkhanany, A. M., Akinhanmi, M. O., Lilyquist, J., Thomas, A., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4499-7 · Cited by 107

CD8+ Tumor-Infiltrating T Cells Are Trapped in the Tumor-Dendritic Cell Network

Boissonnas, A., Licata, F., Poupel, L., Jacquelin, S., Fetler, L., Krumeich, S., Théry, C., Amigorena, S., & Combadière, C. (2013) · Neoplasia · doi:10.1593/neo.121572 · Cited by 104

Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies

Shih, K. C., Arkenau, H., & Infante, J. R. (2014) · Drugs · doi:10.1007/s40265-014-0305-6 · Cited by 109

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies

Bouwstra, R., van Meerten, T., & Bremer, E. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.943 · Cited by 111

Chemotherapy Broadens the Range of Tumor Antigens Seen by Cytotoxic CD8+ T Cells in Vivo

Jackaman, C., Majewski, D., Fox, S. A., Nowak, A. K., & Nelson, D. J. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1307-4 · Cited by 105

Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death

Blasio, S. D., Wortel, I. M. N., van Bladel, D. A. G., de Vries, L. E., Boer, T. D., Worah, K., de Haas, N., Buschow, S. I., de Vries, I. J. M., Figdor, C. G., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1192739 · Cited by 107

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer

Huang, K. C., Chiang, S., Chen, W. T., Chen, T.-W., Hu, C., Yang, P.-C., Ke, T., & Chao, K. S. C. (2020) · Cancers · doi:10.3390/cancers12020462 · Cited by 105

Regulatory and effector functions of gamma–delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer

Paul, S., & Lal, G. (2016) · International Journal of Cancer · doi:10.1002/ijc.30109 · Cited by 109

Immunogenic anti-cancer chemotherapy as an emerging concept

Haynes, N. M., der Most, R. G. V., Lake, R., & Smyth, M. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.008 · Cited by 104

Oncolytic viruses and immunity

Chaurasiya, S., Chen, N. G., & Fong, Y. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.008 · Cited by 108

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Funt, S. A., Lattanzi, M. W., Whiting, K. A., Al‐Ahmadie, H. A., Quinlan, C., Teo, M. Y., Lee, C., Aggen, D. H., Zimmerman, D. E., McHugh, D. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01485 · Cited by 112

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

Fotin‐Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. M., & Kallen, K. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2605 · Cited by 103

Turning Tumors into Vaccines: Co-opting the Innate Immune System

van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 106

Harnessing cancer immunotherapy during the unexploited immediate perioperative period

Matzner, P., Sandbank, E., Neeman, E., Zmora, O., Gottumukkala, V. N. R., & Ben‐Eliyahu, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0319-9 · Cited by 104

Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects

Loenhout, J. V., Peeters, M., Bogaerts, A., Smits, E., & Deben, C. (2020) · Antioxidants · doi:10.3390/antiox9121188 · Cited by 108

Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer

Farren, M. R., Mace, T. A., Geyer, S. M., Mikhail, S., Wu, C. S.-Y., Ciombor, K. K., Tahiri, S., Ahn, D. H., Noonan, A. M., Villalona-Calero, M. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1732 · Cited by 101

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer

Tian, Y., Zhai, X., Han, A., Zhu, H., & Yu, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0753-2 · Cited by 104

Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives

Roger, S., Jelassi, B., Couillin, I., Pelegrín, P., Besson, P., & Jiang, L. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.029 · Cited by 103

Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy

Ramakrishnan, R., Huang, C., Cho, H.-I., Lloyd, M. C., Johnson, J., Ren, X., Altiok, S., Sullivan, D. M., Weber, J. S., Celis, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2236 · Cited by 108

Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity

Kang, T. H., Mao, C.-P., Lee, S. Y., Chen, A. J., Lee, J., Kim, T. W., Alvarez, R. D., Roden, R. B. S., Pardoll, D. M., Hung, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4241 · Cited by 104

Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance

Liu, Y., Zhang, X., Zhou, M., Nan, X., Chen, X., & Zhang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b14577 · Cited by 101

The macrophage: a key player in the pathophysiology of peripheral neuropathies

Msheik, Z., Massry, M. E., Rovini, A. M. F., Billet, F., & Desmoulière, A. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02454-6 · Cited by 108

ISCOMATRIX vaccines mediate CD8+ T‐cell cross‐priming by a MyD88‐dependent signaling pathway

Wilson, N. S., Yang, B., Morelli, A. B., Koernig, S., Yang, A., Loeser, S., Airey, D., Provan, L., Hass, P., Braley, H., et al. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.71 · Cited by 102

Chemoimmunotherapy

Emens, L. A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb5066 · Cited by 101

The immune cell atlas of human neuroblastoma

Verhoeven, B. M., Mei, S., Olsen, T. K., Gustafsson, K. U., Valind, A., Lindström, A., Gisselsson, D., Fard, S. S., Hagerling, C., Kharchenko, P. V., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100657 · Cited by 100

Inflammation, Aging, and Cancer: Tumoricidal Versus Tumorigenesis of Immunity

Khatami, M. (2009) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-009-9059-2 · Cited by 100

Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation

Chisholm, R. H., Lorenzi, T., & Clairambault, J. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.009 · Cited by 99

SMAD4 promotes TGF-β–independent NK cell homeostasis and maturation and antitumor immunity

Wang, Y., Chu, J., Yi, P., Dong, W., Saultz, J. N., Wang, Y., Wang, H., Scoville, S. D., Zhang, J., Wu, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121227 · Cited by 100

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy

Sterman, D. H., Alley, E. W., Stevenson, J. P., Friedberg, J. S., Metzger, S. T., Recio, A., Moon, E. K., Haas, A. R., Vachani, A., Katz, S. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2133 · Cited by 97

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Lai, A. Y., Sorrentino, J. A., Dragnev, K. H., Weiss, J., Owonikoko, T. K., Rytlewski, J. A., Hood, J. V. W., Zhao, Y., Malik, R. K., Strum, J. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000847 · Cited by 100

The immunosuppressive side of PDT

Mróz, P., & Hamblin, M. R. (2011) · Photochemical & Photobiological Sciences · doi:10.1039/c0pp00345j · Cited by 99

Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer

Ramakrishnan, R., & Gabrilovich, D. I. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1390-6 · Cited by 97

Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy

Liu, Y., Chen, X., Yang, P., Qiao, Z., & Wang, H. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.8b01510 · Cited by 99

Boosting Checkpoint Immunotherapy with Biomaterials

Liu, L., Pan, Y., Zhao, C., Huang, P., Chen, X. S., & Rao, L. (2023) · ACS Nano · doi:10.1021/acsnano.2c11691 · Cited by 97

Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity

Stojanovska, V., Sakkal, S., & Nurgali, K. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00212.2014 · Cited by 96

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy

La-Beck, N. M., & Gabizón, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00416 · Cited by 96

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Nishida, S., Koido, S., Takeda, Y., Homma, S., Komita, H., Takahara, A., Morita, S., Ito, T., Morimoto, S., Hara, K., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000020 · Cited by 94

An immunologic portrait of cancer

Ascierto, M. L., Giorgi, V. D., Liu, Q., Bedognetti, D., Spivey, T., Murtas, D., Uccellini, L., Ayotte, B. D., Stroncek, D. F., Chouchane, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-146 · Cited by 94

VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity–Induced Tumor Regression

Doloff, J. C., & Waxman, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3380 · Cited by 95

Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment

Kang, T. H., Park, J. H., Yang, A. D., Park, H. J., Lee, S., Kim, Y. S., Jang, G.-Y., Farmer, E. A., Lam, B. K., Park, Y.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14821-z · Cited by 94

New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma

Bo, M. D., Mattia, E. D., Baboçi, L., Mezzalira, S., Cecchin, E., Assaraf, Y. G., & Toffoli, G. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100702 · Cited by 94

Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance

Medler, T. R., Cotechini, T., & Coussens, L. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.07.008 · Cited by 97

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 88

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328